Your browser is no longer supported. Please, upgrade your browser.
BCLI Brainstorm Cell Therapeutics Inc. daily Stock Chart
Brainstorm Cell Therapeutics Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own1.00% Shs Outstand31.15M Perf Week-22.44%
Market Cap373.89M Forward P/E- EPS next Y-0.55 Insider Trans-5.43% Shs Float25.12M Perf Month-24.24%
Income-27.70M PEG- EPS next Q-0.25 Inst Own20.10% Short Float18.05% Perf Quarter-30.65%
Sales- P/S- EPS this Y-52.20% Inst Trans1.07% Short Ratio7.48 Perf Half Y77.10%
Book/sh0.83 P/B12.95 EPS next Y39.10% ROA-144.70% Target Price22.33 Perf Year183.64%
Cash/sh0.83 P/C12.98 EPS next 5Y- ROE-339.90% 52W Range3.58 - 17.95 Perf YTD151.17%
Dividend- P/FCF- EPS past 5Y-9.40% ROI- 52W High-40.11% Beta0.72
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low200.28% ATR1.31
Employees32 Current Ratio4.70 Sales Q/Q- Oper. Margin- RSI (14)34.52 Volatility19.18% 10.34%
OptionableYes Debt/Eq0.00 EPS Q/Q43.10% Profit Margin- Rel Volume1.19 Prev Close10.19
ShortableYes LT Debt/Eq0.00 EarningsOct 15 BMO Payout- Avg Volume605.72K Price10.75
Recom2.00 SMA20-28.89% SMA50-23.57% SMA20015.21% Volume721,641 Change5.55%
Dec-19-16Reiterated Maxim Group Buy $5 → $6
Dec-22-15Reiterated Maxim Group Buy $14 → $5
Oct-23-20 05:30AM  
Oct-22-20 09:00AM  
Oct-19-20 07:57AM  
Oct-16-20 06:00AM  
Oct-15-20 07:00AM  
Oct-12-20 06:00AM  
Oct-09-20 06:51AM  
Oct-02-20 01:00AM  
Sep-30-20 05:00AM  
Sep-29-20 06:00AM  
Sep-16-20 07:30AM  
Sep-03-20 09:00AM  
Sep-02-20 08:30AM  
Aug-25-20 07:39AM  
Aug-19-20 08:13AM  
Aug-10-20 09:03AM  
Aug-07-20 05:50AM  
Aug-05-20 07:00AM  
Jul-27-20 07:58AM  
Jul-23-20 04:36PM  
Jul-09-20 09:10AM  
Jul-08-20 05:31AM  
Jul-02-20 06:49AM  
Jul-01-20 08:50AM  
Jun-25-20 08:26AM  
Jun-24-20 09:06AM  
Jun-23-20 05:45AM  
Jun-15-20 09:00AM  
Jun-11-20 07:28AM  
Jun-10-20 05:40AM  
Jun-09-20 06:00AM  
Jun-04-20 07:09PM  
Jun-03-20 06:00AM  
Jun-02-20 06:00AM  
May-27-20 07:25AM  
May-18-20 06:06AM  
May-08-20 05:35AM  
May-07-20 06:30AM  
May-04-20 03:30AM  
Apr-29-20 06:00AM  
Apr-08-20 06:40AM  
Apr-03-20 06:59AM  
Apr-01-20 09:00AM  
Mar-31-20 04:00AM  
Mar-16-20 03:00AM  
Mar-06-20 09:25AM  
Feb-27-20 01:00AM  
Feb-20-20 05:10AM  
Feb-18-20 07:00AM  
Feb-17-20 01:00AM  
Feb-11-20 06:00AM  
Feb-10-20 01:00AM  
Feb-04-20 04:45AM  
Jan-29-20 04:00AM  
Jan-21-20 09:53AM  
Jan-17-20 06:00AM  
Jan-07-20 01:00AM  
Jan-03-20 10:21AM  
Dec-19-19 05:00AM  
Dec-18-19 05:00AM  
Dec-11-19 05:00AM  
Nov-26-19 08:05AM  
Nov-25-19 06:00AM  
Nov-21-19 06:15AM  
Nov-20-19 07:00AM  
Nov-18-19 06:32AM  
Nov-14-19 08:07AM  
Nov-13-19 05:00AM  
Nov-12-19 01:00AM  
Nov-05-19 06:15AM  
Oct-28-19 07:45AM  
Oct-25-19 01:00AM  
Oct-24-19 08:45AM  
Oct-23-19 01:00AM  
Oct-11-19 01:00AM  
Oct-07-19 08:04AM  
Oct-02-19 06:45AM  
Sep-27-19 04:00AM  
Sep-19-19 09:19AM  
Sep-09-19 01:00AM  
Sep-06-19 01:50AM  
Aug-16-19 10:30AM  
Aug-13-19 07:30AM  
Aug-05-19 01:00AM  
Jul-10-19 07:08AM  
Jul-02-19 08:15AM  
May-31-19 01:00AM  
May-30-19 01:00AM  
May-28-19 01:00AM  
May-21-19 10:15AM  
May-13-19 01:00AM  
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Setboun DavidEVP and COOJul 16Buy12.955,00064,74055,000Jul 16 05:10 PM
ACC International Holdings LtdMember of 10% owner groupJul 16Sale13.477,823105,35167,053Jul 16 05:05 PM
Abbhi SankeshDirectorJul 15Buy12.9946,779607,6592,164,530Jul 16 05:15 PM
ACC International Holdings LtdMember of 10% owner groupJul 15Sale13.1218,430241,71574,876Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 13Sale13.5240,000540,95293,306Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 10Sale13.352,00026,700133,306Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 09Sale13.133,50045,939135,306Jul 16 05:05 PM
Shah PreetamEVP, CFO and TreasurerDec 24Buy3.9611,60045,92936,600Dec 27 07:01 AM
Kern Ralph Dr.COO and Chief Medical OfficerDec 24Buy3.883,00011,640115,655Dec 27 07:01 AM
Araya ArturoChief Commercial OfficerDec 24Buy3.903,00011,7008,608Dec 27 07:00 AM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.